32 results about "Middle East respiratory syndrome" patented technology

The invention discloses a middle east and respiratory syndrome coronavirus antibody and a preparation method thereof, and belongs to the technical field of cell-mediated immunity. RDB protein of an MERS-CoV virus S protein receptor binding domain is obtained by using in-vitro expression and purification of a baculovirus expression vector system, and Bab / c mice are immunized by using high-purity MERS RBD protein, an efficient antiviral neutralizing anti-body is screened by the methods such as an enzyme-linked immuno sorbent assay (ELISA), a false virus neutralization experiment and the like. The antibody and the crystal structure of the MERS RBD protein are analyzed, and a crucial amino acid of the antibody combined with viral proteins is determined from the molecular level. Thus, the antibody is further humanized, and the possibility is provided for clinical detection, prevention and treatment of MERS-CoV virus infection.

A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.

The present invention provides systems and methods for assessing a disease. Medical imaging data of lungs of a patient is received. The lungs are segmented from the medical imaging data and abnormality regions associated with a disease are segmented from the medical imaging data. An assessment of the disease is determined based on the segmented lungs and the segmented abnormality regions. The disease may be COVID-19 (coronavirus disease 2019) or diseases, such as, e.g., SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome), or other types of viral and non-viral pneumonia.

The present invention belongs to the field of biomedicine, and relates to compounds represented by formula I, stereoisomers, mixtures thereof, or pharmaceutically acceptable salts thereof. The present invention also relates to the use of said compound, its stereoisomer, mixture, or pharmaceutically acceptable salt in the preparation of treatment and / or prevention of MERS-CoV infection or diseases associated with MERS-CoV infection (such as Middle East Respiratory Syndrome) use in medicines. (Z-Ile-Glu-X 1 ‑Ile‑Val‑Lys‑Lys‑Ile‑X 2 -X 3 ‑Ile‑Glu‑Arg‑Ala‑Ile‑Glu‑Ala‑Gln‑Gln‑X 4 ‑Leu‑Leu‑Gln‑Leu‑Thr‑Val‑Trp‑X 5 ‑Ile‑Lys‑Gln‑Leu‑Gln‑Ala‑Arg‑Ile‑Leu‑B)n (I).

The invention discloses fluorescent RT-PCR (reverse transcription-polymerase chain reaction) primers and a fluorescent probe for detecting MERS (Middle East Respiratory Syndrome) coronavirus, which comprise a first primer pair, a second primer pair and a probe, wherein the first primer pair, second primer pair and fluorescent probe are a first specific forward / reverse primer pair, a second specific forward / reverse primer pair and a fluorescent probe which are respectively designed for conserved sequences of two different genes of the MERS coronavirus. The invention also discloses a kit and method for detecting the MERS coronavirus. By using the two specific probe pairs and primer which are designed for the conserved sequences of the two different genes of the MERS coronavirus, when the double-target PCR (polymerase chain reaction) detection result is positive, the infection of the MERS coronavirus in the clinical sample can be diagnosed. The method is simple, has the characteristics of high speed, high specificity and high sensitivity, and can be used for auxiliary diagnosis and epidemic situation monitoring of the MERS coronavirus.

An immunogenic CD40-targeted trimeric MERS-CoV S1 fusion polypeptide as well as a corresponding polynucleotide encoding it and its use for safely inducing immune responses directed against MERS-CoV without inducing vaccine associated respiratory pathologies associated with non-targeted vaccines.